CJC-1295 cost and pricing: what it actually runs in 2026

Last updated 2026-07-26

How much does CJC-1295 actually cost per vial?

Most CJC-1295 (no-DAC, sometimes called Mod GRF 1-29) sells for roughly $60 to $110 per vial, with vial sizes usually between 2mg and 5mg. CJC-1295 with DAC costs more, typically $90 to $180 per vial, because the Drug Affinity Complex modification is a more involved synthesis and purification job. Those ranges come from scanning current listings across research chemical suppliers, not from a single price sheet, so treat them as a market snapshot rather than a fixed number. Prices shift with peptide purity claims, batch size, and how much testing documentation the seller provides. A useful reference point: FDA's nomination docket for bulk drug substances under Section 503A has included CJC-1295 among substances nominated for compounding review, part of the agency's ongoing evaluation of which peptides can legally be compounded ^[1]. That nomination history is part of why pricing varies so much. Suppliers selling into a stricter, provider-reviewed pipeline generally charge more than anonymous research-chemical storefronts, because testing and chain-of-custody cost real money. If you're comparing listings, price per milligram is the only fair comparison. A $70 vial that contains 2mg costs $35/mg. A $95 vial with 5mg costs $19/mg. The higher sticker price is often the better deal.

Why does CJC-1295 with DAC cost more than no-DAC?

CJC-1295 with DAC costs more because DAC (Drug Affinity Complex) is a separate chemical modification bonded onto the base peptide, and that extra step adds real manufacturing cost and complexity. The DAC portion binds to serum albumin, which is the entire reason it extends the peptide's half-life from roughly 30 minutes (no-DAC) to several days ^[2]. That half-life difference is well documented in the pharmacology literature. The original study describing CJC-1295 with DAC found a half-life of approximately 8 days in humans after a single subcutaneous injection, with sustained elevation of GH and IGF-1 levels over that period ^[2]. No-DAC CJC-1295 (Mod GRF 1-29) clears much faster, consistent with native GHRH's short half-life of a few minutes. That longer half-life is exactly why DAC costs more to produce and why dosing frequency drops. No-DAC needs daily or even multiple-times-daily dosing to keep GHRH receptor stimulation going. DAC versions get dosed roughly once or twice weekly. Fewer vials used per month can offset some of the higher per-vial price, but not always, since DAC vials also tend to be smaller in mg terms per dose. For a full breakdown of which one fits which use case, see CJC-1295 DAC or no-DAC.

What drives the price difference between suppliers?

Five factors explain almost all of the price spread you'll see across listings: purity testing, vial concentration, batch consistency, packaging/cold-chain handling, and whether the seller publishes third-party certificates of analysis (COAs). Third-party HPLC and mass spec testing is the single biggest cost driver behind legitimate price premiums. Running a batch through an independent lab costs the supplier real money per batch, and that cost gets passed through. A seller who never mentions a COA is either not testing or not disclosing, and neither is a good sign. Cold-chain handling matters too. Lyophilized peptide is fairly stable at room temperature for short shipping windows, but proper suppliers still ship with cold packs and track transit time, which adds a few dollars per order. See CJC-1295 storage and shelf life for what temperature exposure does to the peptide. Batch consistency is the quiet variable. A supplier running small, frequent batches has more quality control overhead than one running large runs infrequently. Neither is inherently better, but it affects unit cost. Finally, sellers operating through a provider-reviewed pathway, where a licensed prescriber is actually involved in the decision, tend to price higher than anonymous drop-shipped research chemical stores. That premium buys you a real medical check, more than a peptide.

How much does adding ipamorelin add to the cost?

Ipamorelin typically costs $40 to $80 per vial (usually 5mg), which adds a meaningful chunk to a combined protocol. Since CJC-1295 and ipamorelin are dosed together in most protocols reported in practice, a lot of people budget for both from the start. The rationale for pairing them is mechanistic, not settled clinical proof. CJC-1295 is a GHRH analogue, meaning it works on the GHRH receptor to increase the number of somatotroph cells releasing GH. Ipamorelin is a ghrelin receptor agonist (a GH secretagogue), working through a separate receptor pathway. Combining a GHRH analogue with a ghrelin mimetic is a well-established pharmacological logic, since earlier human studies combining GHRH with GH-releasing peptides (GHRPs) found synergistic, more than additive GH release compared to either compound alone ^[3]. But that additive effect research is mostly older, smaller studies on related compounds, not large trials of this specific pairing at self-administered doses. Nobody has run a large randomized trial specifically on CJC-1295 plus ipamorelin at the doses commonly discussed online, so treat claims of dramatically superior outcomes from stacking as reasonable pharmacological logic, not proven clinical fact. Cost-wise, budgeting for both peptides together, a monthly supply commonly runs $150 to $350 depending on dose and vial size, which we break down in the next section.

What's a realistic monthly cost for a CJC-1295 protocol?

A realistic monthly cost for CJC-1295 alone (no-DAC, daily dosing) runs about $90 to $250, depending on dose size and vial concentration. Adding ipamorelin brings a typical combined monthly total to roughly $150 to $350. Here's a rough table based on common vial sizes and typical listed prices (not a specific protocol recommendation, just a cost model): | Item | Vial size | Typical price | Vials/month (daily dosing) | Monthly cost |

Why is CJC-1295 so expensive compared to other peptides?

CJC-1295 isn't unusually expensive as peptides go, but it costs more than simple amino acid chains because of its length and the DAC modification when present. No-DAC CJC-1295 is a 29-amino-acid peptide (a modified GRF 1-29 fragment), which puts it in the mid-range of synthesis complexity compared to shorter peptides like ipamorelin (a pentapeptide, 5 amino acids). Longer peptide chains have more coupling steps during solid-phase synthesis, and each step has some yield loss. More amino acids generally means more purification passes to hit a usable purity threshold, and that shows up in the final price. DAC versions cost more on top of that because the albumin-binding domain has to be conjugated correctly, and getting that reaction clean without excess unbound DAC contaminating the batch takes tighter process control. Compare that to something like BPC-157 (15 amino acids, no modification), which usually costs less per mg than CJC-1295 with DAC, largely because it's shorter and has no half-life-extending modification to synthesize. Peptide cost roughly tracks chain length plus modification complexity, not marketing hype.

Is a cheaper CJC-1295 vial ever a red flag?

Yes. A price that sits well below the typical $60-$110 no-DAC range, or $90-$180 DAC range, is a signal to slow down and check what you're actually buying, not a signal you found a deal. Common reasons for suspiciously cheap listings: underfilled vials (less actual peptide mass than labeled), degraded or improperly lyophilized product, no COA or a recycled/fake COA, or the vial containing a cheaper substitute peptide entirely. None of these are hypothetical; they're the standard failure modes reported anecdotally across peptide forums and are exactly why third-party testing exists as a check. FDA's consumer guidance on compounded drugs states plainly that these products, unlike FDA-approved drugs, do not go through the agency's premarket review process for safety and effectiveness before reaching patients ^[4]. That is precisely why sourcing through a pathway with actual quality oversight matters more for a compounded peptide than for an off-the-shelf approved medication. If a listing has no batch number, no COA, and a price 30-40% under the market range, that's not a bargain. That's a vial you can't verify.

Does the DAC vs no-DAC choice change total cost over a month, more than per vial?

Yes, and this is where people miscalculate. No-DAC CJC-1295 needs frequent dosing (commonly daily or near-daily in protocols discussed in the literature and practitioner guides) because its half-life is roughly 30 minutes ^[2]. That means you burn through vial contents faster in absolute terms, even though each vial costs less. DAC CJC-1295, with its roughly 8-day half-life ^[2], gets dosed far less often, often once or twice a week. Fewer injections per month can mean fewer total mg used per month even though each mg costs more. Run the math both ways before assuming one is cheaper. A no-DAC protocol using 100mcg daily for 30 days uses 3mg/month. A DAC protocol using 2mg once weekly uses about 8mg/month. Depending on per-mg pricing, either one can come out ahead. There's no universal answer here; it depends on the specific dose and vial pricing you're looking at.

How does provider-reviewed sourcing affect the price you pay?

Provider-reviewed sourcing, where a licensed prescriber evaluates whether a compounded peptide is appropriate before it ships, typically costs more than anonymous research-chemical purchasing, and that premium buys something specific: a real medical check plus a fulfillment pharmacy with actual pharmacy licensing and testing obligations, rather than an unregulated overseas lab. CJC-1295 Co works within that provider-reviewed model, connecting people to a pharmacy partner rather than shipping raw research chemicals with no clinical oversight. That's a meaningfully different product than a vial ordered from a site with no prescriber involvement at all, even if the sticker price is higher. The price gap exists because pharmacy compounding under a prescription involves real regulatory obligations. Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, sets conditions under which compounded human drugs are exempt from certain FDA requirements, tying that exemption to a valid patient-specific prescription and compounding by a licensed pharmacist or physician ^[5]. A supplier operating outside that framework doesn't carry those costs, which is part of why its prices look lower and why the comparison isn't apples to apples. For readers deciding how to source at all, how to get CJC-1295 and CJC-1295 for sale cover the practical steps and what to check before paying anyone.

What other costs come with CJC-1295 beyond the vial itself?

Beyond the peptide vial, you need bacteriostatic water for reconstitution (roughly $10-$20 for a 30mL vial that lasts many reconstitutions), insulin syringes (often sold in packs of 100 for $10-$15), and alcohol swabs. Many protocols also involve routine bloodwork to check IGF-1 levels and general metabolic markers, which isn't optional if you're serious about tracking whether anything measurable is happening. Basic IGF-1 lab panels through direct-to-consumer lab services commonly run $50-$100 per test, and repeating that every few months adds a real recurring cost most people forget to budget for. A sharps disposal container is a small but legally relevant cost in many states, since household trash disposal of used needles is restricted in a number of jurisdictions. The CDC's guidance on safe sharps disposal notes that most states have specific regulations or programs covering how used needles must be handled outside a healthcare setting, so check your own state or local health department's guidance before assuming you can just toss syringes in the trash ^[6]. Proper injection technique also matters for both safety and not wasting product; see CJC-1295 injection sites for site rotation guidance that helps avoid wasted doses from poor absorption at overused sites.

Is there a cost difference between research-chemical and prescription-pathway CJC-1295?

Yes, usually 20-50% higher for the prescription/provider-reviewed pathway, and that gap reflects the layers of oversight involved, more than markup. A prescriber consultation, a licensed compounding pharmacy, batch testing tied to pharmacy accreditation standards, and legitimate customer support all cost money that an anonymous research-chemical seller simply doesn't carry. FDA is explicit that compounded drugs are not FDA-approved and do not undergo the agency's premarket review for safety, efficacy, and manufacturing quality ^[4]. That's true whether you buy through a provider-reviewed pathway or an anonymous seller. The difference is that a provider-reviewed pathway adds independent human judgment and a licensed pharmacy's own quality systems on top of that baseline, while an anonymous research-chemical seller adds nothing beyond whatever it claims about its own testing. Whether that premium is worth it depends on your risk tolerance and how much you value having a prescriber actually look at your situation before you inject anything. For a compound with a molecular mechanism this specific (GHRH receptor agonism, dependent on precise dosing and mg accuracy), the argument for paying for oversight is stronger than it would be for something with a wider margin of safety.

Frequently asked questions

How much does CJC-1295 cost per vial?

No-DAC CJC-1295 typically costs $60-$110 per vial (usually 2-5mg). CJC-1295 with DAC runs $90-$180 per vial because the DAC modification adds synthesis complexity. Price per mg is the fairer comparison across listings, since vial sizes vary.

Why does CJC-1295 with DAC cost more than without DAC?

DAC (Drug Affinity Complex) is a separate chemical addition that binds serum albumin, extending the peptide's half-life to roughly 8 days versus about 30 minutes for no-DAC ^[2]. Conjugating that domain cleanly adds real manufacturing and purification cost, which shows up as a higher per-vial price.

How much does a month of CJC-1295 and ipamorelin cost together?

A combined monthly protocol commonly runs $150-$350, depending on vial sizes, dose, and dosing frequency. CJC-1295 alone typically runs $90-$250/month; ipamorelin adds roughly $40-$160/month depending on how many vials you use.

Is cheaper CJC-1295 ever a good deal?

Rarely. Prices well under the typical $60-$110 (no-DAC) or $90-$180 (DAC) range usually mean underfilled vials, no real testing, or a substituted product. Check for a batch-specific certificate of analysis before assuming a low price is a bargain.

Does DAC or no-DAC cost less over a full month?

It depends on your dosing frequency and per-mg price, more than the vial sticker price. No-DAC needs daily dosing and burns more total mg per month; DAC needs weekly dosing and uses less mg overall but costs more per mg. Run the actual monthly mg math before deciding.

Why is CJC-1295 more expensive than some other peptides?

CJC-1295 no-DAC is a 29-amino-acid peptide, longer than short peptides like ipamorelin (5 amino acids), so it needs more synthesis steps and purification passes. The DAC version adds an albumin-binding modification on top, which further raises production cost.

Does buying through a provider-reviewed pathway cost more than research-chemical sellers?

Usually, by roughly 20-50%. That premium pays for a prescriber's actual evaluation and a licensed pharmacy's compounding and testing standards, versus an anonymous seller with no clinical oversight. FDA notes compounded drugs don't get premarket safety review regardless of source ^[4], so oversight quality varies by pathway, not by price alone.

What extra supplies add to the real cost of a CJC-1295 protocol?

Bacteriostatic water ($10-$20 per 30mL vial), insulin syringes ($10-$15 per 100), alcohol swabs, a sharps container, and periodic IGF-1 bloodwork ($50-$100 per test) all add up. These recurring costs are easy to forget when budgeting off the vial price alone.

Why is CJC-1295 usually paired with ipamorelin, and does that add cost?

CJC-1295 works on the GHRH receptor while ipamorelin works on the ghrelin receptor, a separate pathway. Older combined GHRH-plus-GHRP research shows synergistic, more than additive GH release from combining pathways ^[3], though no large trial has tested this exact pairing at typical self-administered doses. Ipamorelin adds $40-$80 per vial to the total.

How does reconstitution affect the real cost per dose?

How much bacteriostatic water you use to dissolve the peptide determines your concentration and how many actual doses you get from one vial. More dilution water and smaller per-dose draws stretch a vial further, meaning two people buying an identical vial can end up with very different real monthly costs.

Are there legal restrictions that affect CJC-1295 pricing?

CJC-1295 has appeared among substances nominated for FDA's 503A bulk drug substances review ^[1], and pharmacy compounding under Section 503A (21 U.S.C. 353a) requires a valid prescription and licensed compounding ^[5]. Sellers operating outside that legal framework avoid those compliance costs, which is part of why their prices can look lower.

What's a fair price per milligram for CJC-1295?

For no-DAC, roughly $20-$40 per mg is typical based on current market listings. For DAC versions, expect $35-$60 per mg given the added synthesis cost. Always calculate price per mg rather than comparing raw vial prices, since vial sizes differ widely across sellers.

Sources

1. FDA, 503A Bulk Drug Substances Nomination Docket (Docket No. FDA-2013-N-1525): CJC-1295 has been nominated as a bulk drug substance for 503A compounding review
2. Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006, PMID 16352683: CJC-1295 with DAC has a half-life of approximately 8 days and produces sustained GH/IGF-1 elevation after a single dose
3. Bowers et al., synergistic GH release from combined GHRH and GHRP administration, PMID 2394779: Combining a GHRH analogue with a ghrelin-receptor-agonist GH secretagogue produces more than additive GH release compared to either compound alone
4. FDA, "Compounding and the FDA: Questions and Answers" (2018): Compounded drugs do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality
5. 21 U.S.C. 353a, Federal Food, Drug, and Cosmetic Act Section 503A: Section 503A ties compounding exemptions to a valid prescription and licensed pharmacy or physician compounding
6. CDC, "Sharps Disposal" guidance from the National Institute for Occupational Safety and Health / CDC Injection Safety program: Household trash disposal of used needles is restricted in a number of jurisdictions and most states have specific regulations covering sharps disposal